FindTrial
Sign In

Effectiveness and Safety of Ripertamab in the Treatment of Primary Membranous Nephropathy: A Retrospective Study

ectiveness and Safety of Ripertamab in the Treatment of Primary Membranous Nephropathy: A Retrospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094211
Enrollment
Unknown
Registered
2024-12-18
Start date
2024-12-18
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Membranous Nephropathy

Interventions

PLA2R-negative Group:None
PLA2R-positive Group:None

Sponsors

Department of Nephrology, Zhongshan Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with primary membranous nephropathy confirmed by renal biopsy or positive serum PLA2R antibodies. 2. Adult patients aged >=18 years. 3.Signed informed consent and willingness to participate in this study and to be followed up.

Exclusion criteria

Exclusion criteria: 1.Patients with secondary membranous nephropathy or a combination of other renal diseases or severe complications. 2.Patients with hypersensitivity to ripertamab or its components. 3.Pregnant or lactating women. 4.Patients who were unable to complete follow-up or refused to participate in the study.

Design outcomes

Primary

MeasureTime frame
Remission rate (including complete and partial remission);—

Secondary

MeasureTime frame
Serum albumin level;Estimated tubular filtration rate (eGFR);Anti-PLA2R antibody titer;CD19/CD20 expression;—

Countries

China

Contacts

Public ContactLiangxiang Xiao

Department of Nephrology, Zhongshan Hospital of Xiamen University

liangxiangxiao@xmu.edu.cn+86 185 5902 5963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026